Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Inventors”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 361 records · Page 20Linked to original sources
PubMed2005

Enzyme immunoassay (EIA)/enzyme-linked immunosorbent assay (ELISA).

This brief note addresses the historical background of the invention of the enzyme immunoassay (EIA) and enzyme-linked immunosorbent assay (ELISA). These assays were developed independently and simultaneously by the research group of Peter Perlmann and Eva Engvall at Stockholm University in Sweden and by the research group of Anton Schuurs and Bauke van Weemen in The Netherlands. Today, fully automated instruments in medical laboratories around the world use the immunoassay principle with an enzyme as the reporter label for routine measurements of innumerable analytes in patient samples. The impact of EIA/ELISA is reflected in the overwhelmingly large number of times it has appeared as a keyword in the literature since the 1970s. Clinicians and their patients, medical laboratories, in vitro diagnostics manufacturers, and worldwide healthcare systems owe much to these four inventors.

Animals↗
PubMed2003

Intellectual property law: a primer for scientists.

Intellectual property (IP) is a generic legal term for patents, copyrights, and trademarks, which provide legal rights to protect ideas, the expression of ideas, and the inventors and creators of such ideas. A patent provides legal protection for a new invention, an application of a new idea, discovery, or concept that is useful. Copyright provides legal protection from copying for any creative work, as well as business and scientific publications, computer software, and compilations of information. A trademark provides rights to use symbols, particular words, logos, or other markings that indicate the source of a product or service. A further method of benefiting from an invention is simply to keep it secret, rather than to disclose it a trade secret. IP impinges on almost everything scientists do. As scientists are paid to come up with ideas and aspire to patent and/or publish their work, the protection of ideas and of written works especially should be of interest and concern to all.

Biochemistry↗
PubMed2000

James Beall Morrison: the visionary who revolutionized the practice of dentistry.

BACKGROUND AND OVERVIEW: For centuries, dental patients sat on makeshift contraptions or modified straight-backed chairs, which took a toll on the health of both patient and dentist. In addition, the lack of a suitable drill retarded the development of restorative dentistry, allowing minimum care for only a tiny segment of the population. One farseeing American dentist, James Beall Morrison, changed all that in the 1870s with his innovative, fully adjustable chair, which made sitdown dentistry possible. Moreover, his monumental invention of the foot-powered drill allowed dentists to place restorations that were theretofore impossible. Dentists the world over became able to treat patients more comfortably and satisfactorily, and with less stress to themselves. CLINICAL IMPLICATIONS: A newly discovered collection of letters in the Smithsonian Institution to Morrison from colleagues in London provides insight into how collaboration between inventor and user helped bring about great changes in the way dentistry is practiced. These letters also shed light on what dentistry was like one and one-quarter centuries ago, how far dentistry has come and what changes may be forthcoming.

Dental Cavity Preparation↗
PubMed2003

What's true and whose idea was it?

In this paper, the author explores the idea that psychoanalysis at its core involves an effort on the part of patient and analyst to articulate what is true to an emotional experience in a form that is utilizable by the analytic pair for purposes of psychological change. Building upon the work of Bion, what is true to human emotional experience is seen as independent of the analyst's formulation of it. In this sense, we, as psychoanalysts, are not inventors of emotional truths, but participant observers and scribes. And yet, in the very act of thinking and giving verbally symbolic 'shape' to what we intuit to be true to an emotional experience, we alter that truth. This understanding of what is true underlies the analytic conception of the therapeutic action of interpretation: in interpreting, the analyst verbally symbolizes what he feels is true to the patient's unconscious experience and, in so doing, alters what is true and contributes to the creation of a potentially new experience with which the analytic pair may do psychological work. These ideas are illustrated in a detailed discussion of an analytic session. The analyst makes use of his reverie experience--for which both and neither of the members of the analytic pair may claim authorship--in his effort to arrive at tentative understandings of what is true to the patient's unconscious emotional experience at several junctures in the session.

Expressed Emotion↗
PubMed1998

[Screening test by statistically reducing the number of the State-Trait Anxiety Inventory (STAI) items].

The purpose of the study is to find a method of mental examination which can be simply performed concurrently with physical examination during a regular check-up. On a regular check-up, the state-trait anxiety inventor (STAI) was administered to 264 construction workmen engaged in reconstruction work for the Hanshin Awaji Great Earthquake. Data on a total of 40 STAI items, i.e., 20 state anxiety (A-State) items and 20 trait anxiety (A-Trait) items were subjected to multiple regression analysis and five items were extracted from A-State and five from A-Trait items as a practical tool for a simple screening test. The contribution rates of the respective five items for the total score were 90.0% for A-State and 88.5% for T-State. The correlation coefficients, r, between predicted and observed values were 0.949 (p < 0.01) for A-State and 0.940 (p < 0.01) for A-Trait. Because of certain degrees of validity and reliability of each five-item system, it is considered that this method is useful as a simple screening test to roughly grasp the mental health of subjects and can be utilized for mental health care at offices.

Adult↗
PubMed2006

Outstanding scientist of the year 2006: Rogel Patawaran, BS.

Rogel Patawaran is cofounder of iQSecure Solutions, Inc., a secure web mail company, which began in 2002 and is currently based in Santa Monica, California. Its unique service enables hospitals, clinics, and doctors' offices the opportunity to have secure web-based video and telephone conferencing by simply switching online services offered by this innovative company. In addition, he is cofounder of AuthoTecq, based in Long Beach, California, and inventor of the AuthoTecq system in 1999. The AuthoTecq system is an online credit card processing company. Rogel Patawaran sought to remedy one of the problems facing users of internet transactions. Because internet merchants act as their own gateway for financial transactions, they have been storing credit card numbers in their own databases, thereby failing to address the necessary security provisions involved in the storage of such sensitive information. AuthoTecq removes this responsibility from the merchant by processing financial transactions on behalf of the merchants. Its system dramatically reduces credit card theft, and thereby decreases the amount of credit card fraud. In his landmark book Saving Lives & Saving Money, Newt Gingrich, former Speaker of House of Representatives, describes a new approach to the challenge of creating a better system of personal health and health care for the 21st century, a system that saves lives and saves money. He indicates that you could be visiting a clinic with electronic medical records, electronic laboratory reports, and electronic drug prescriptions. This entirely electronic clinic saves money and lives because it is far more accurate than a paper system. Such clinics exist at the Kaiser Permanente Hospitals, the Mayo Clinic in Jacksonville, Florida, the Cleveland Clinic, many Harvard hospitals, and all Veteran Administration hospitals in the US. He indicates that healthcare is the only industry in America that can give you a disease and then charge you to cure it. He further reports that out of 100 hospital patients, five or six will be the victim of a preventable error. He states that medication errors alone kill 7000 people each year, adding $2 billion to the overall cost of healthcare. He stresses that these 7000 needless deaths are not only unacceptable but un-American as well. During the 1990s, the pharmaceutical industry sought help from the Food and Drug Administration (FDA) to develop a standard by which a paperless system could be adopted for healthcare. In March of 1997, the FDA issued its final ruling, which established the criteria for which the FDA will recognize the transmission of authenticity within electronic data as well as establishing standards of authenticity for electronic data equivalent to the validity of signatures on paper documents and records. The FDA also recognizes the growth that can be experienced by converting healthcare technology to a paperless system, such as the expediting of patient files in a more organized manner, increasing the speed of file transfer of such documents, reducing prescription errors, enabling computer-generated data analysis and statistics, and reducing storage space. Rogel Patawaran and his colleagues also realized that electronic healthcare technology using the highest standard of data encryption to transfer data could also dramatically improve the safety of patients in our nation and the world. To answer the needs within healthcare technology, Rogel Patawaran created a system for healthcare providers using the most superior encryption methods, and in the process creating iQSolutions, Inc. Its web mail system uses the Public Key Infrastructure (PKI) format, which is the strongest known encryption format. PKI is used in combination with the Advance Encryption Standard (AES) digital encryption algorithm, which is the current algorithm used by banks and government agencies, thereby protecting the privacy and accuracy of the information. Rogel Patawaran's remarkable contributions to the encryption process will aid in the number of lives saved as well as helping to avoid medical malpractice by ensuring the accuracy of medical records, as well as reducing the number of medication errors or inappropriate prescriptions being filled. These remarkable accomplishments in patient safety are accomplished at a rapid speed that ensures that data-sensitive patient files can be securely transmitted between and within hospitals. Finally, with the growing need for an electronic system within the medical field, doctors will be able to securely access all such data from anywhere and at any time, thus reducing the age-old problem of time constraints that a paper system presented doctors and hospitals alike. In recognition of Rogel Patawaran's contributions to the medical field through the use of encryption teamed with the transferring of sensitive data such as hospital records, Rogel Patawaran has been selected as the Outstanding Scientist of 2006.

Artificial Intelligence↗
PubMed2004

ABI 007.

ABI 007 [Abraxane] is an albumin-stabilised nanoparticle formulation of paclitaxel designed to overcome insolubility problems encountered with paclitaxel. This then eliminates the need for toxic solvents like cremophor, which limits the dose of paclitaxel that can be administered and hence affect overall drug efficacy. Studies have shown that the albumin receptor-mediated paclitaxel-transport mechanism is analogous to the opening of a 'trapdoor' on the endothelial cell wall within blood vessels. This facilitates the passage of ABI 007 from the bloodstream via the blood vessels to the underlying tumour tissue. ABI 007 is being developed for the treatment of a variety of tumour types by American Pharmaceutical Partners. In addition to the standard infusion formulation of ABI 007, oral and pulmonary delivery formulations are also being investigated. American Pharmaceutical Partners, a subsidiary of American BioScience, secured exclusive North American marketing and manufacturing rights to ABI 007 from American BioScience in November 2001. In anticipation of product launch within the fourth quarter of 2004, the company formed Abraxis Oncology and recruited an experienced sales and marketing team. The company has also accumulated approximately 28 million US dollars of paclitaxel inventory. As such, American Pharmaceutical Partners anticipates pre-launch expenses to cost approximately 40 million US dollars, incurred over 2004. In addition, the company expects to make two milestone payments worth 10 million US dollars as well as 15 million US dollars, based upon US FDA acceptance of NDA filing in the second quarter of 2004 and subsequent US FDA approval, respectively. The milestone for US FDA approval would be capitalised and amortised over the estimated life of the product.Previously, American Pharmaceutical Partners reported that its rolling NDA submission for ABI 007 commenced in May 2003. In July 2003, the company announced that this was progressing on schedule and expected to have completed its entire NDA submission by the end of 2003. The company also began preparations to form a sales and marketing group in anticipation of product launch. In addition, production of commercial quantities of ABI 007 was expected to begin in the second half of 2003. The US FDA granted fast-track status to ABI 007 for this indication in January 2003. The decision for NDA filing was based on the successful completion of a phase III trial evaluating ABI 007 versus standard paclitaxel among 460 patients with metastatic breast cancer in the US. In September 2003, American Pharmaceutical Partners and American BioScience jointly announced positive interim results from the trial, which shows that the primary efficacy objective had been exceeded. American BioScience completed this phase III trial in early 2003 with the results unblinded in mid-2003. The phase III study directly compared the efficacy of ABI 007 260 mg/m(2) versus paclitaxel 175 mg/m(2). Both agents were administered every 3 weeks. ABI 007 was administered as a 30-minute infusion without steroid pretreatment. Paclitaxel-treated patients received steroid pretreatment and the drug was administered over 3 hours. Enrollment was completed in December 2002 with 460 first- and second-line metastatic breast cancer patients enrolled. A Data Monitoring Committee concluded in October 2002 that a sample-size adjustment of the phase III trial was not required and that the study could be continued to completion. A phase II trial of ABI 007 was also underway in metastatic breast cancer patients who have failed taxane therapy. The trial was evaluating a weekly rather than 3-weekly regimen of ABI 007. Also in February 2004, American BioScience initiated a multicentre phase II trial in patients with metastatic melanoma. The trial will evaluate both chemotherapy-naive patients (at a dose of 150 mg/m(2) administered weekly) and patients who have previously received chemotherapy (at a dose of 100 mg/m(2) administered weekly) as treatment for metastatic disease. In May 2003, American Pharmaceutical Partners reported that ABI 007 is also being evaluated for the treatment of non-small cell lung cancer, ovarian cancer, melanoma and cervical cancers. Phase I/II trials have also been conducted in other solid tumours, including squamous cell cancer of the head and neck, and pelvis. Phase I trials have also been conducted in patients with solid tumours to evaluate the administration of ABI 007 on a weekly schedule. In September 2003, American BioScience was issued US patent No. 6,506,405, which has 89 claims covering compositions of matter and unit dosage forms. In addition, the patent covers methods of use without the requirement for pretreatment with steroid therapy or growth factor support. In July 2003, the US Court of Appeals for the Federal Circuit in Washington DC unanimously ruled that American BioScience is the true and rightful owner of patent No. 5,780,653. This patent covers three next-generation taxane anticancer compounds. This ruling overturned a lower court decision in a lawsuit brought in 1998 by Florida State University (FSU) and FSU Prof. Robert Holton's privately held company, Taxolog. In the lawsuit, FSU and Taxolog alleged that Prof. Holton and others at FSU were the true inventors of the compounds claimed under American BioScience's patent.

Albumin-Bound Paclitaxel↗
PubMed1995

Eugene W. Caldwell Lecture. Why Caldwell?

Every year for the past 75 years, the American Roentgen Ray Society has honored Eugene W. Caldwell by including the Caldwell Memorial Lecture as one of the features of the society's annual meeting. In this anniversary year--a year that highlights the history of radiology--it is appropriate to look back on Caldwell's career to examine the reasons for the society's decision to honor him, rather than numerous other eminent radiologists who might have been selected in his place. In the first Caldwell lecture in 1920, Walter Alvarez said, "Caldwell was a pioneer, an inventor, a research worker, a versatile, enthusiastic, and lovable man" [1]. Surely, many radiologists who lived during Caldwell's lifetime and who came later--including some living today--can be described in this way. The purpose of this essay is to offer an explanation of why Caldwell was chosen over the others.

History, 19th Century↗
PubMed2005

Jan Mikulicz-Radecki: one of the creators of world surgery.

This paper presents the life and achievements of Professor Jan Mikulicz-Radecki and his contribution to European and world surgery. He was born in 1850. Four periods can be distinguished in his surgical career: (1) Vienna period, 1875-82, when he worked by the side of the great Theodor Billroth: he introduced a number of new diagnostic and operative techniques, aseptic and antiseptic procedures, published research papers. He made the first endoscope for examining the esophagus and stomach. (2) Cracow period, 1882-87, when he was head of the Department of Surgery: he inaugurated his work with a lecture in Polish, which started: Gentlemen, I have been accused that I do not know the Polish language--which is my mother tongue to me as well as to any of you. He published papers on the use of iodophorm for healing wounds, was the first surgeon who sutured a perforated gastric ulcer (1885) and invented pyloroplasty (1887), nowadays called Heinecke-Mikulicz pyloroplasty. (3) Konigsberg period, 1887-90: he improved the technique of gastric resection, worked on surgery for peptic ulcer and advocated aseptic and antiseptic procedures. (4) Wroclaw (Breslau) period, 1890- 1905: Mikulicz was appointed head of a newly founded Surgical Department. He rebuilt it and designed one of the largest and most modern operating theaters in Europe that time. He introduced silk gloves for operations for the first time in the world. In 1892 he described bilateral swelling of salivary and lacrimal glands, called Mikulicz's syndrome; in 1902 he published his experience with two-stage colon resection; and in 1904 he described ostitis fibrosa cystica juvenilis. Called "a king in the kingdom of surgeons", he was one of the fathers of the world's modern surgery; having a brilliant surgical mind, he was a pioneer of many new operations and an inventor of surgical tools, permanently assimilated in the world's surgery.

Digestive System Surgical Procedures↗
PubMed1977

Undergraduate self-perceptions of creativity and independence.

596 undergraduate students from 7 schools of a major university responded to a group of 20 questions relating to self-perceptions of creativity and independence employed in earlier studies of graduate faculty members and industrial inventors and producers. The hypothesis was that these students would tend to perceive of themselves in terms of popular expectations relating to the schools of their choice. The results indicated that students of architecture, engineering, liberal arts, and science tend to see themselves as significantly more independent, individualistic, and creative than students of business, education, and to some extent, agriculture.

Achievement↗
PubMed2001

Personality change as defensive responses of patients evaluated for liver transplant.

Patients affected by endstage liver disease and awaiting liver transplant suffer very stressful conditions. The aim of this study was to evaluate the person ality and behavioral responses of a group of liver transplant candidates, 95 men (M age 50 yr.) and of a group of 18 normal men (M age 49 yr.). The 16 Personality Factor Questionnaire of Cattell, and the PSY Inventory for Behavioral Assessment were administered to assess personality and behavior. On the 16PF Questionnaire, patients had significantly different mean scores from normal subjects on Scale B- (low mental capacity), G (conformity), N (shrewdness), and Q1- (conservatism). They also showed a somewhat lower but not a statistically significant mean on Scale E (submissiveness). In addition, on the four second-order factors of the 16PF (Anxiety, Control, Pathemia, and Extraversion) patients had a significantly higher mean on Control. With respect to PSY Inventors factors, patients showed impairment in energy, sleep, sexual disturbances, and obsessive behaviors. It appears these patients with endstage liver disease, who were evaluated for liver transplant, showed psychological regressive functioning, i.e., high control and dependency on medical staff, submissiveness, which are interpretable as defensive responses to upcoming transplant.

Adult↗
PubMed2005

Inventions leading to the development of the diagnostic test kit industry--from the modern pregnancy test to the sandwich assays.

The universities are encouraged by the government nowadays to stimulate innovations and also to provide the proper machinery for assisting the protection and commercialisation of innovations. A better understanding of the innovation process may help to create an atmosphere suitable for inventions at the university. Examples can be taken from successful innovations previously made at the university. During the 1960's I made a series of inventions, which ultimately led to the development of the diagnostic test kit industry. The first, which I made as an undergraduate, was a simple and reliable test kit for diagnosis of pregnancy. This was followed by the solid phase radioimmunoassay and a solid phase assay for vitamin B12; next, the dual specific non-competitive sandwich assay and the in-vitro test for diagnosis of allergy, called RAST (Radioallergosorbent test). Organon in Holland with the pregnancy test kit, and Pharmacia in Sweden with test kits for radioimmunoassay, became pioneers among the diagnostic test kit industries. Pharmacia Diagnostics later became one of the leading diagnostic test kit companies in the world and has continued to be so in the field of allergy diagnosis. Each one of these inventions started with a few unique observations leading to a technical development. The pregnancy test as well as the allergy test emerged from the development of assay methods with unique qualities with the subsequent search for appropriate applications. The foreseeing of a commercial value on a future market was a very important step. This was followed by the search for a suitable industry interested to exploit the invention with its new business opportunity i.e. apply for a patent, produce and market the products, which in my case consisted of the necessary reagents and equipments for particular diagnostic tests. Finally, an agreement had to be settled between the entrepreneur and the inventors. This report describes these inventions and particularly discusses some crucial steps of the innovation processes.

Binding, Competitive↗
PubMed2005

George W. Crile, Ohio's first neurosurgeon, and his relationship with Harvey Cushing.

Much has been written about Harvey Cushing, his contributions to neurosurgery, and his relationship with many of his contemporaries. Nevertheless, there is no independent report documenting his relationship with Ohio's first neurosurgeon, George W. Crile. Crile's role as a neurosurgeon is limited to the late nineteenth and early twentieth centuries, and he is best remembered for other accomplishments. Father of physiological surgery, pioneering surgeon, innovator, inventor, soldier, and the principal founder of the Cleveland Clinic Foundation, Crile lived during the golden era of surgery, when the discipline was evolving from a crude and chancy art to an applied science. Crile achieved distinction by performing and describing the first successful radical neck dissection for head and neck cancers and the first successful direct human-to-human blood transfusion. He helped introduce the measurement of blood pressure during surgery, first used cocaine for regional anesthesia in the US, proposed "anoci-anesthesia" to prevent shock during surgery, helped establish one of the first nurse anesthetist schools, and invented the Crile forceps and the pneumatic suit, which was the forerunner to the aviator's antigravity suit. He was a founding member of the American College of Surgeons, its second president (1916-1917), and chairman of the Board of Regents (1913-1939). Crile was a teacher, lecturer, and author who published more than 400 papers and 24 books. In this report the authors trace the relationship between Crile and Cushing from their initial competition for a staff surgeon's position to their common interest in blood pressure, and their roles in the American Ambulance in France and later in World War I.

Anesthesia, General↗
PubMed2005

[One hundred years after the Geminal law, Rene Cerbelaud publishes secret remedies].

Our colleague René Cerbelaud was an original character. He played an important part in the pharmaceutical history of the 20th century when published recipes of countless medicines and cosmetic products, incurring the hostility of their manufacturers. As a matter of fact, he contributed to the disappearance of secret remedies and therefore to the enforcement of the Germinal law more than a century after it was promulgated. In a sense he may be looked on as the inventor of generic drugs and the promoter of what has become "parapharmacie".

Cosmetics↗
PubMed2006

[A pharmacist art lover, Charles-Honoré Thévenot].

Set up in Dijon (Côte-d'Or), the pharmacist Charles-Honoré Thévenot (1812-1894) is mainly known as being the inventor of an industrial process for manufacturing and filling the medicamentous capsules. It was also a great art lover which had joined together an important collection of engravings and drawings. It was bequeathed to the town of Dijon and now constitues one of the jewels of its Museum of Fine Arts.

Art↗
PubMed2003

Robert Hooke's model of memory.

In 1682 the scientist and inventor Robert Hooke read a lecture to the Royal Society of London, in which he described a mechanistic model of human memory. Yet few psychologists today seem to have heard of Hooke's memory model. The lecture addressed questions of encoding, memory capacity, repetition, retrieval, and forgetting--some of these in a surprisingly modern way. Hooke's model shares several characteristics with the theory of Richard Semon, which came more than 200 years later, but it is more complete. Among the model's interesting properties are that (1) it allows for attention and other top-down influences on encoding; (2) it uses resonance to implement parallel, cue-dependent retrieval; (3) it explains memory for recency; (4) it offers a single-system account of repetition priming; and (5) the power law of forgetting can be derived from the model's assumptions in a straightforward way.

Animals↗
PubMed1991

Thought police. Healthcare executives must carefully guard intellectual property developed in their facilities.

Healthcare executives should have a working knowledge of intellectual property law--the legal principle that, for a limited period, treats intangible ideas and concepts as if they were products or property. Not only should administrators be aware of how to protect their facilities' patents, trademarks, copyrights, and trade secrets, but they must also be sure that employees in their own facilities do not infringe on the intellectual property of others. A patent is granted when an inventor proposes a useful new process, machine, "article of manufacture," or composition of matter, including any new and useful improvement on existing items in these same categories. A trademark is a name, symbol, device, or combination thereof adopted and used by an institution to identify its goods or services and to distinguish them from its competitors' goods or services. Expressions of ideas and thoughts set forth in words, sentences, paragraphs, sketches, pictures, graphs, or any other means of conveying ideas or concepts commonly understood to be works of authorship--both published and unpublished--may be protected by a copyright. Trade secret law applies to those who might misappropriate information that has been given to them because of their special relationship with the holder of the trade secret (i.e., through employment, contract, or other fiduciary or trust relationship).

Confidentiality↗
PubMedDate not supplied

The case of the high-risk safety product.

After several days of meetings, J.F. Winchester, president of MDC Industries, felt no closer to a decision. MDC, a manufacturer of wall and ceiling panels, was considering whether to exercise an option to buy a new and safer wallboard technology. The product was being touted as revolutionary, but, Winchester wondered, could MDC afford to carry the flag? According to its inventor, Robert Goerner, Smoke-Safe would be a vast improvement over standard safety-rated wallboard. With almost the same flame-retardant properties, Smoke-Safe had the advantage of giving off almost no fumes or smoke in fire tests. And, Winchester knew, most fire-related deaths are from smoke, not flames. Indeed, the numbers were grimly persuasive: 82% of fire-related injuries involving standard panels were caused by smoke inhalation. What's more, Smoke-Safe would cost about the same to manufacture as MDC's current wallboard. But MDC had several other good options for spending the $5 million Goerner was asking; building plastics was only one of its profit centers. And the prospect of launching a campaign to change building codes in order to market Smoke-Safe, which could spark a fight with competitors, was daunting. Since its current wallboard gave MDC only 18% of the wallboard market, many industry insiders speculated whether MDC had the market clout to influence major cities to revise their codes. Six experts in marketing, law, and ethics advise MDC Industries on how it can balance ethical and business imperatives in making its decision.

Consumer Product Safety↗